Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Weigel, Ralf [VerfasserIn]   i
 Weber, Tillmann [VerfasserIn]   i
 Schmiedek, Peter [VerfasserIn]   i
Titel:Management of primary central nervous system lymphoma
Verf.angabe:R. Weigel, T. Weber, P. Schmiedek
Jahr:1999
Umfang:8 S.
Fussnoten:Gesehen am 24.03.2022
Titel Quelle:Enthalten in: Oncology research and treatment
Ort Quelle:Basel : Karger, 2014
Jahr Quelle:1999
Band/Heft Quelle:22(1999), 6, Seite 464-471
ISSN Quelle:2296-5262
Abstract:Primary central nervous system lymphomas (PCNSLs) are predominantly high-grade diffuse large B-cell lymphomas. Incidence has been rising in immunocompetent as well as in immunocompromised patients, but main characteristics like age of onset, sex distribution, CT/MRI appearance and localization, molecular biology and morphology are different in both groups. These characteristics explain only in part the poor prognosis of the latter group. In today’s neurosurgical practice PCNSL is regarded as a special entity among malignant brain tumors. This is due to the fact that surgical resection is no longer the treatment of choice ever since successful radio-/chemotherapy regimens have been introduced. Thus, in cerebral lesions suspicious of PCNSL, the histopathological diagnosis should be established by CT- or MRI-guided stereotactic biopsy or by CSF cytology. One should abstain from corticosteroid administration before stereotactic biopsy as this would mask the tumor’s morphological appearance and possibly render an accurate histological diagnosis impossible. Postoperative tumor staging depends on the favored theory of histiogenesis. There is still a controversial discussion about the need to exclude systemic disease. Absolutely mandatory are a full clinical examination, enhanced CT or MRI images from the brain, CSF cytology, bone marrow biopsy, slit-lamp examination, and an HIV test. Today’s therapy consists of corticosteroids and a methotrexate-based chemotherapy with adjuvant radiotherapy. As an exception, cyclophosphamide, methotrexate, procarbacine and dexamethasone (CMPD) administered after blood-brain barrier disruption with mannitol are at least as effective as multimodality treatment with methotrexate plus radiation therapy. More aggressive regimens did not prove superior regarding survival but result in a higher therapy-related complication rate.
DOI:doi:10.1159/000027023
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1159/000027023
 Volltext: https://www.karger.com/Article/FullText/27023
 DOI: https://doi.org/10.1159/000027023
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1796590525
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68899313   QR-Code
zum Seitenanfang